Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.617. It has been cited 22 times, with 21 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.147
From 10 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 21 citers.
Bristol-Myers Squibb Co.
Grant: N/A
Clinical Translational Science Award
Grant: 1UL1 TR003167, UM1 TR0045906
MD Anderson Cancer Center
Grant: NIH/NCI P30 CA016672
NCI NIH HHS
Grant: P30 CA016672
NCATS NIH HHS
Grant: UL1 TR003167
National Institutes of Health
Grant: 3UL1TR003167-02S4
Center for Clinical and Translational Sciences (CCTS)
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
FWCI
8.39
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords